Sol-Gel Technologies Ltd.(SLGL)Earnings, Financials & Key Ratios
SLGL•NASDAQ
$74.12
Price updated Jul 6, 2026
AboutSol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; and Erlotinib, Tapinarof, and roflumilast to treat psoriasis and other medical conditions. It is also involved in the development of generic topical dermatological drug products. The company has collaboration with Perrigo. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.Show more
- Revenue$19M+68.0%
- EBITDA-$7M+36.9%
- Net Income-$6M+42.1%
- EPS (Diluted)-2.20-478.9%
- Gross Margin100%+2.1%
- EBITDA Margin-38.32%+62.5%
- Operating Margin-38.88%+62.7%
- Net Margin-31.6%+65.5%
- ROE-23.72%+24.3%
SLGL Price & Volume
Sol-Gel Technologies Ltd. (SLGL) stock price & volume — 10-year historical chart
Loading chart...
Persistent Clinical R&D Costs Challenge Sol-Gel Solvency
Investment Thesis • Updated 2024Q2
VerdictNegative: The company's inability to generate positive operating cash flow over the last ten quarters
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Liquidity and dilution risk
Key Thesis Takeaways
- Sol-Gel Technologies faces a precarious financial outlook characterized by extreme revenue volatility and a reliance on non-recurring milestone payments to offset heavy R&D expenditures.
- While the company achieved a 55.1% gross margin in 2024Q2, the lack of consistent commercial pull-through and an accumulated deficit of $224.7 million suggest significant long-term sustainability risks.
- Investors should monitor the company's ability to extend its $11.5 million cash runway, as current operating losses necessitate potential dilutive financing to support its proprietary dermatology pipeline.
Verdict Logic
combined with a declining cash balance of $11.5 million, presents a high risk of shareholder dilution.
SLGL Growth Metrics
Sol-Gel Technologies Ltd. (SLGL) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years17.19%
3 Years70.92%
TTM282.9%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM66.87%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM70.22%
Return on Capital
10 Years-156.41%
5 Years-31.61%
3 Years-43.72%
Last Year-27.76%
SLGL Recent Earnings
Sol-Gel Technologies Ltd. (SLGL) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 4/12 qtrs (33%)
Q2 2026Latest
May 28, 2026Metric
Actual
Est
EPS
$1.31+54.2%
$2.86
Rev
$108,000-88.0%
$900,000
Q2 2026
Mar 19, 2026Metric
Actual
Est
EPS
$1.07-374.4%
$0.39
Rev
$7M+0.0%
$7M
Q2 2026
Mar 11, 2026Metric
Actual
Est
EPS
$0.39+0.0%
$0.39
Rev
$7M+0.0%
$7M
Q4 2025
Nov 20, 2025Metric
Actual
Est
EPS
$2.13-1.9%
$2.09
Rev
$400,000-93.8%
$7M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 28, 2026 | $1.31vs $2.86+54.2% | $108,000vs $900,000-88.0% |
| Q2 2026 | Mar 19, 2026 | $1.07vs $0.39-374.4% | $7Mvs $7M+0.0% |
| Q2 2026 | Mar 11, 2026 | $0.39vs $0.39+0.0% | $7Mvs $7M+0.0% |
| Q4 2025 | Nov 20, 2025 | $2.13vs $2.09-1.9% | $400,000vs $7M-93.8% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Sol-Gel Technologies Ltd. (SLGL)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $74.12 | $208.27M | -33.69 | 68.04% | -31.6% | -23.72% | — | |
| $7.22 | $198.71M | -15.36 | 10.2% | -14.82% | -35.57% | — | |
| $11.09 | $1.53B | -1.08 | -2.75% | -43.5% | -50.65% | — | |
| $0.67 | $28.55M | -1.08 | 13.77% | -4726.21% | -69.57% | — | |
| $0.75 | $97.84M | -4.72 | -10.02% | -2.03% | -9.41% | — | |
| $3.08 | $1.07B | 36.11 | 0.57% | 3.74% | 4.75% | — |
Compare SLGL vs Peers
Sol-Gel Technologies Ltd. (SLGL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when SLGL posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
SLGL Frequently Asked Questions
Sol-Gel Technologies Ltd. (SLGL) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Sol-Gel Technologies Ltd.'s revenue?
Sol-Gel Technologies Ltd. (SLGL) reported $6.6M in revenue for fiscal year 2025.
How fast is Sol-Gel Technologies Ltd. growing?
Sol-Gel Technologies Ltd. (SLGL) grew revenue by 68.0% over the past year. This is strong growth.
Is SLGL profitable?
Sol-Gel Technologies Ltd. (SLGL) reported a net loss of $14.9M for fiscal year 2025.
Dividend & Returns
What is SLGL's return on equity?
Sol-Gel Technologies Ltd. (SLGL) has a return on equity (ROE) of -23.7%. Negative ROE indicates the company is unprofitable.
What is Sol-Gel Technologies Ltd.'s free cash flow?
Sol-Gel Technologies Ltd. (SLGL) generated $0.3M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.